News Articles
- COURSE trial shows importance of biomarker testing in COPD
- Breakthroughs in Targeting KRAS G12C Mutations in NSCLC
- Burden of Lung Cancer Care and Treatment Takes a Toll Beyond Pocketbooks
- Time from Diagnosis to Treatment: A Risk Factor in Aggressive Non-Hodgkin Lymphomas
- Improving β-cell Function in Prediabetes and Early T2D: Metformin or Gastric Banding?
- Sleep Disturbance Increases Risk of Chronic Pain, and Gender Matters
- Direct-Acting Antivirals in Chronic Hepatitis C Treatment
- New Guideline Focuses on Chronic Hepatitis C Treatment in Primary Care Setting
Feature Articles & Mini-Reviews
- Novel obesity medications open door to new era in treatment of OSA
- BTK Inhibitor Success Puts Focus on Resistance Mechanisms
- Dana-Farber/ Harvard Cancer Center Cancer Epidemiology Program: Pan Life-Span Population Studies Beyond Odds Ratios and P-Values
- Dana-Farber/ Harvard Cancer Center Winter 2018 eNews: Clinical Trial Spotlight
- Therapeutic Inhibition of XPO1-Mediated Nucleocytoplasmic Transport With SINE Technology
Manuscript Development
- Isatuximab, carfilzomib, lenalidomide, and dexamethasone induction in newly diagnosed myeloma: analysis of the MIDAS trial
- International Myeloma Society/International Myeloma Working Group Consensus Recommendations on the Definition of High-Risk Multiple Myeloma
- Practical Aspects of Immunotherapy: A Report from the 20th International Myeloma Society (IMS) Annual Meeting
- Phase III double-blind study comparing the efficacy and safety of proposed biosimilar MYL-1402O and reference bevacizumab in stage IV non-small-cell lung cancer
White Papers
- Transition of Care Across the CAR T-Cell Therapy Continuum: Implications and Best Practices for the Clinical Team
- Selinexor: Best Practices for Optimizing Treatment
Peer-Reviewed Publications
- Regulation of estrogen receptor alpha by the SET7 lysine methyltransferase
- The enzymatic basis of processivity in lambda exonuclease
Needs Assessments
Consumer Health Articles
Additional samples available on request.